四環醫藥(00460.HK)旗下軒竹生物與天晴康方達成聯合治療合作協議
格隆匯5月30日丨四環醫藥(00460.HK)宣佈,集團旗下軒竹生物科技股份有限公司("軒竹生物"),與正大天晴康方(上海)生物醫藥科技有限公司("天晴康方")達成聯合治療合作協議,據此,協議雙方就軒竹生物的AXL抑制劑與天晴康方的派安普利PD-1單抗將展開聯合探索實驗,共同開發聯合治療在實體瘤中的應用。
此次合作,將充分發揮軒竹生物在小分子靶向治療領域和康方生物在大分子腫瘤免疫治療的專業優勢,探索免疫聯合療法在非小細胞肺癌等領域的應用,惠及更多癌症患者。
據悉,AXL抑制劑是一款高選擇性口服小分子產品。作為酪氨酸蛋白激酶TAM家族(Tyro3、AXL和Mer)成員,AXL與其配體GAS6在許多惡性腫瘤中有高表達和活化。GAS6-AXL信號通路作為促進腫瘤生長及轉移、腫瘤免疫逃逸與藥物耐受的關鍵通路之一,被認為是癌症治療的新靶點。該產品目前正在北美地區進行I/II期臨牀研究。
派安普利PD-1單抗產品由中國生物製藥集團與中山康方聯合開發,早前已獲得中國國家藥品監督管理局("藥監局")批准上市,用於治療至少經過二線系統化療復發或難治性經典型霍奇金淋巴瘤患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.